FDA approves new breast cancer treatment
On Sept. 28, the U.S. Food and Drug Administration (FDA) approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2…
Reader Survey
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.
